synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
=== Upstanders === In September 2016, Starbucks announced a debut of its first-ever original content series called "Upstanders", which aimed to be inspirational. The series featured podcasts, written word, and video, and was distributed via the Starbucks mobile app, online, and through the company's in-store digital network.
=== Neurotransmission === Inhibitory neurons in the central nervous system play a homeostatic role in the balance of neuronal activity between excitation and inhibition. Inhibitory neurons using GABA, make compensating changes in the neuronal networks preventing runaway levels of excitation. An imbalance between excitation and inhibition is seen to be implicated in a number of neuropsychiatric disorders.
=== Photocatalysis === Being smaller than the wavelengths of visible light, nanoparticles can be dispersed in transparent media without affecting its transparency at those wavelengths. This property is exploited in many applications, such as photocatalysis.
In the two examples (on the right) the isoelectric point is shown by the green vertical line. In glycine the pK values are separated by nearly 7 units. Thus in the gas phase, the concentration of the neutral species, glycine (GlyH), is effectively 100% of the analytical glycine concentration. Glycine may exist as a zwitterion at the isoelectric point, but the equilibrium constant for the isomerization reaction in solution
Sources: en.wikipedia.org
The first inhabitants of North America migrated from Siberia at least 15,000 years ago, either across the Bering land bridge or along the now-submerged Ice Age coastline. Human footprints at White Sands National Park have been dated to about 21,000–23,000 years ago. The Clovis culture, which appeared around 11,000 BCE in North America, is believed to be the first widespread culture in the Americas. Over time, Indigenous North American cultures grew increasingly sophisticated, and some, such as the Mississippian culture, developed agriculture, architecture, and complex societies. In the post-archaic period, the Mississippian cultures were located in the midwestern, eastern, and southern regions, and the Algonquian in the Great Lakes region and along the Eastern Seaboard, while the Hohokam culture and Ancestral Puebloans inhabited the Southwest. Native population estimates of what is now the United States before the arrival of European colonizers range from around 500,000 to nearly 10 million. In 2024, an estimated 3.43 million people in the United States identified as American Indian or Alaska Native alone (thus, identifying with no other racial category) and represented approximately 1% of the U.S. population. An additional 5.68 million people identified as American Indian or Alaska Native in combination with one or more other races, bringing the total of those identifying as American Indian or Alaska Native to approximately 9.11 million.
== History == Resonance ionization was first used in a spectroscopy experiment in 1971 at the Institute for Spectroscopy Russian Academy of Sciences; in that experiment, ground state rubidium atoms were ionized using ruby lasers. In 1974, a group of photophysical researchers at the Oak Ridge National Laboratory led by George Samuel Hurst developed, for the first time, the resonance ionization process on helium atoms. They wanted to use laser light to measure the number of singlet metastable helium, He (21S), particles created from energetic protons. The group achieved the selective ionization of the excited state of an atom at nearly 100% efficiency by using pulsed laser light to pass a beam of protons into the helium gas cell. The experiment on singlet metastable helium atoms was seminal in the journey towards using resonance ionization spectroscopy (RIS) for extensive atomic analysis in research settings.
== History == In the first half of the 20th century there were first attempts to protect people from malaria. At the beginning Pasteur's approach of developing bacterial vaccines was used as a big hope in eradication of this fatal disease. But inactivated malaria sporozoites were ineffective in inducing the protection. In 1948 inactivated merozoites with an adjuvant were used for preventing lethal malaria to kill a group of monkeys. But the strong toxicity of the adjuvant and inability to obtain sufficient count of parasites from human blood stopped further efforts in this way. In 1967 irradiated malaria sporozoites (extracted from salivary glands of infected mosquitos) induced immune response in mice without the need of the adjuvant and similar evidence obtained in human volunteer trials. The mice were exposed to irradiated mosquitos infected by malaria parasites. Mice and volunteers did not acquire malaria because mosquitos and the sporozoites were irradiated and their immune cells triggered response that could protect them from following infection. Yet this approach was not further developed due to problems with obtaining sufficient number of sporozoites and with the harvesting of parasites. Later, modern adjuvants and the possibility of preparing of single parasite proteins provided another way to create a malaria vaccine. RTS,S is a subunit vaccine based on coat protein of sporozoites of the Plasmodium falciparum.
Sources: en.wikipedia.org
small conditional RNA (scRNA) A class of small RNA molecules engineered so as to change conformation conditionally in response to cognate molecular inputs, often with the goal of controlling signal transduction pathways in vitro or in vivo.
=== 2024: United Cup champion, two Masters titles and French Open final === Alongside Team Germany, Zverev competed and won the United Cup, saving two championship points in his singles match against Hubert Hurkacz and defeating Team Poland in the final. In Melbourne, he reached the quarterfinals of the 2024 Australian Open, defeating Dominik Koepfer, Lukas Klein for his 400th career win, Alex Michelsen, and Cameron Norrie, with two matches requiring deciding set tiebreakers. He then achieved his first-ever win against a top-5 player at a Grand Slam, defeating Carlos Alcaraz in four sets in the quarterfinals, to make his first Australian Open semifinal appearance since 2020. He subsequently lost to Danill Medvedev, despite being two sets to love up. His defeat marked only his second loss from being up two sets to love in a 5-set match, his first being against Dominic Thiem in the final of the 2020 US Open. In Mexico, Zverev reached the semifinals in Los Cabos with straight sets wins against Yoshihito Nishoka and Thanasi Kokkinakis but lost to Jordan Thompson in a deciding set tiebreaker. In Acapulco, Zverev lost to Daniel Altmaier in the first round. Seeded sixth at the BNP Paribas Open, Zverev reached the quarterfinals for the first time since 2021, defeating Christopher O'Connell, Tallon Griekspoor, and Alex de Minaur before losing to eventual champion Carlos Alcaraz. Seeded fourth at the Miami Open, Zverev reached the semifinals, defeating Félix Auger-Aliassime, Christopher Eubanks, Karen Khachanov, and Fábián Marozsán before losing to Grigor Dimitrov.
Caryophyllene (C15H24) → caryophyllene oxide (C15H24O) → 14-hydroxycaryophyllene (C15H24O) → 14-hydroxycaryophyllene oxide (C15H24O2). Caryophyllene oxide, in which the alkene group of caryophyllene has become an epoxide, is the component responsible for cannabis identification by drug-sniffing dogs and is also an approved food additive, often as flavoring. Caryophyllene oxide may have negligible cannabinoid activity.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.